Research Progress of Preoperative Regional-arterial Chemotherapy in Advanced Gastric Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 LIZhen-kai ,  DONGMao-sheng

Department of General Surgery, The Second Artillery General Hospital PLA, Beijing 100088, China;

Corresponding?author：

DONGMao-sheng, Email: 13051186112@163.com

Keywords：

Advanced gastric cancer; Preoperative regional-arterial chemotherapy

DOI：

10.7507/1007-9424.20150369

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the research progress of preoperative regional-arterial chemotherapy in advanced gastric cancer. Method The literatures about the research progress of preoperative regional-arterial chemotherapy in the advanced gastric cancer were reviewed. Results The preoperative regional-arterial chemotherapy in the advanced gastric cancer could decrease the tumour stage, improve the R0 resection rate and the long-term survival rate, effectively improve the drug concentrations of tumor and portal vein, and not only kill or damage cancer cells directly, but also prevent the metastasis of liver and lymph nodes effectively, and reduce the side effects, cause the nuclear pyknosis and fracture of cancer cells in a short time. The course of preoperative regional-arterial chemotherapy in the advanced gastric cancer generally was 4-9 weeks, and then whether the surgery treatment was decided to undergo according to the results of the curative effect evaluation. Conclusions The preoperative regional-arterial chemotherapy in the advanced gastric cancer has more advantages than intravenous chemotherapy, further research of multicenter and large clinical trials, would inaugurate a wider application prospects.

Citation： LIZhen-kai, DONGMao-sheng. Research Progress of Preoperative Regional-arterial Chemotherapy in Advanced Gastric Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(11): 1410-1415. doi: 10.7507/1007-9424.20150369 Copy

1.	?季加孚.胃腸道腫瘤的新輔助治療.中國實用外科雜志, 2005, 5(25):261-263.
2.	左朝暉, 歐陽永忠, 湯明, 等.胃癌的綜合治療研究的進展.中華普外科手術學雜志:電子版, 2012, 6(3):319-324.
3.	Kong SH, Yang HK. Surgical treatment of gastric gastrointestinal stromal tumor. J Gastric Cancer, 2013, 13(1):3-18.
4.	Kosaka T, Ueshige N, Sugaya J, et al. Evaluation of intra-arterial infusion chemotherapy for advanced gastric cancer. Gan To Kagaku Ryoho, 1998, 25(9):1288-1291.
5.	Sugarbaker PH. Adjuvant intraperitoneal chemotherapy for advanced primary gastric cancer. Scand J Surg, 2006, 95(4):270-273.
6.	王義平, 王金林, 何世保, 等.介入動脈灌注化療在晚期胃癌中的療效觀察.中外醫療, 2013, 33(33):22-23.
7.	李東, 吳萍山.術前動脈介入化療治療進展期胃癌的病例對照研究.中國癌癥雜志, 2010, 20(4):290-294.
8.	Ensminger WD. Intrahepatic arterial infusion of chemotherapy:pharmacologic principles. Semin Oncol, 2002, 29(2):119-125.
9.	Pohlen U, Rieger H, Kunick-Pohlen S, et al. PhaseⅡstudy of regional chemotherapy using the hypoxic abdominal perfusion technique in advanced abdominal carcinoma. 5-FU pharmacokinetics, complications and outcome. Anticancer Res, 2007, 27(1B):667-674.
10.	詹曉星, 顏小瓊.介入放射學中的藥代動力學研究.國外醫學:臨床放射學分冊, 1989, 126(6):327-329.
11.	鄒壽椿, 裘華森, 陳方宏, 等.胃癌血供與供血動脈插管化療的臨床觀察.中國實用外科雜志, 1996, 16(11):20-21.
12.	Link H, Aigner KR, Kuehn W, et al. Prospective correlative chemosensitivity testing in high-dose intraarterial chemotherapy for liver metastases. Cancer Res, 1986, 46(9):4837-4840.
13.	Araki K, Yamamoto H, Kobayashi M, et al. Experimental and clinical study on intraoperative local infusion chemotherapy (ILIC) for advanced gastric carcinoma. Gan To Kagaku Ryoho, 1995, 22(11):1531-1534.
14.	Maurer CA, Borner M, Buchler MW, et al. Regional chemotherapy of gastrointestinal cancer. Dig Surg, 1997, 14(1):9-22.
15.	李澍.進展期胃癌術中實施區域性緩釋化療安全性和遠期療效觀察.臨床和實驗醫學雜志, 2014, 13(22):1863-1865.
16.	Shchepotin IB, Chorny V, Hanfelt J, et al. Palliative superselective intra-arterial chemotherapy for advanced nonresectable gastric cancer. J Gastrointest Surg, 2000, 3(4):426-431.
17.	朱志東, 蒲永東.氟尿嘧啶經胃左動脈和外周靜脈化療的藥代動力學比較.中國胃腸外科雜志, 2000, 3(1):28-30.
18.	吳鵬, 朱正綱, 葉正寶, 等. 5-氟尿嘧啶-2'-脫氧核苷經胃左動脈介入灌注后的藥代動力學實驗研究.外科理論與實踐, 2004, 9(2):135-139.
19.	徐光煒.胃癌手術輔助化學療法.北京:人民衛生出版社, 1987:251-259.
20.	劉福坤, 陳忠豪, 李國立, 等.胃癌術前介入治療后血管變化與癌組織壞死的關系.世界華人消化雜志, 1998, 6(8):686-688.
21.	孫碎康, 蒲青凡, 嚴律南, 等.胃癌病人術前選擇性動脈栓塞化療對腫瘤血管的影響.中國普通外科雜志, 2002, 11(4):202-204.
22.	楊秀超, 崔振玉, 李正華.經動脈插管灌注抗癌藥提高胃癌手術療效.中華外科雜志, 1994, 32(7):403-404.
23.	徐工學, 李志霞, 陳佛來, 等.術前區域性動脈灌注化療對大腸癌細胞凋亡相關基因的影響.中華外科雜志, 2001, 39(6):436-439.
24.	蒲青凡, 孫碎康, 劉占培, 等.術前胃動脈化療栓塞對胃癌淋巴結轉移灶癌細胞凋亡的影響.中國普外基礎與臨床雜志, 2006, 13(4):427-430.
25.	徐圣德, 高斌, 文剛, 等.術前動脈化療對進展期胃癌細胞凋亡和增殖的影響.介入放射學雜志, 2007, 16(5):353-356.
26.	彭飛, 陳冬峨, 陳華.胃癌p53癌基因表達的Meta分析.數理醫藥學雜志, 2004, 17(6):540-542.
27.	Fujimoto S, Watanabe Y, Enomoto K, et al. Studies on preoperative cancer chemotherapy. Methods of preoperative intra-arterial infusion by the use of methotrexate or vinblastine. Cancer, 1969, 24(3):433-441.
28.	Peng Z, Xu S, Li H, et al. Advanced gastric cancer with brain metastasis effectively treated by arterial infusionchemotherapy:A case report. Oncol Lett, 2014, 7(2):449-451.
29.	劉銳鋒, 王小琦, 王小虎, 等.術前動脈灌注化療治療局部晚期胃癌的系統評價.腫瘤防治研究, 2012, 39(9):1098-1106.
30.	吳震峰, 朱文強, 曹勤洪, 等.區域動脈灌注化療在進展期胃癌短程新輔助化療中的應用.中華胃腸外科雜志, 2014, 17(11):1092-1095.
31.	Zhang CW, Zou SC, Shi D, et al. Clinical significance of preoperative regional intra-arterial infusion chemotherapy for advanced gastric cancer. World J Gastroenterol, 2004, 10(20):3070-3072.
32.	Fl?rcken A, Schaefer C, Bichev D, et al. Hepatic arterial infusion chemotherapy for liver metastases from gastric cancer:an analysis in Western patients. Tumori, 2011, 97(1):19-24.
33.	Wang YY, Zhang W, Qian S, et al. The effect of locoregional transarterial infusion chemotherapy on liver metastasis after gastric cancer resection. J Int Med Res, 2012, 40(3):1141-1148.
34.	高登鵬, 張霄成, 石秀玲, 等.胃癌術中術后局部化療對癌細胞及患者預后的影響.現代中西醫結合雜志, 2005, 14(19):2535-2537.
35.	李東, 吳萍山, 趙宏.進展期胃癌術前介入化療的療效觀察.腫瘤學雜志, 2003, 9(4):201-203.
36.	李國立, 劉福坤, 陳忠豪, 等.胃癌術前選擇性動脈化療對組織和細胞結構的影響.中華外科雜志, 1997, 35(5):4-6, 66.
37.	肖乾虎, 程中, 盧武勝, 等.胃癌術前行選擇性動脈插管灌注抗癌藥物治療與一般化療的療效比較.臨床外科雜志, 1996, 4(4):190-192.
38.	金雪熙, 楊大明, 徐幼龍, 等.胃癌術前選擇性動脈灌注化療.介入放射學雜志, 2001, 10(6):344-345.
39.	卞育海, 陳治平, 莊捷, 等.術前經動脈化療在胃癌綜合治療中的應用.消化外科, 2002, 1(5):337-339.
40.	Kennedy BJ. The unified international gastric cancer staging classification system. Scand J Gastroenterol, 1987, 22(Suppl 133):11.
41.	Hwang SW, Lee DH, Lee SH, et al. Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography. J Gastroenterol Hepatol, 2010, 25(3):512-518.
42.	Kim EY, Lee WJ, Choi D, et al. The value of PET/CT for preoperative staging of advanced gastric cancer:comparison with contrastenhanced CT. Eur J Radiol, 2011, 79(2):183-188.
43.	Kwee RM, Kwee TC. Role of imaging in predicting response to neoadjuvant chemotherapy in gastric cancer. World J Gastroenterol, 2014, 20(7):1650-1656.
44.	葛梅英, 尹化斌, 葛菁芳, 等.小網膜受胃癌侵犯的CT表現及其對病變擴散蔓延的影響研究.實用放射學雜志, 2014(5):786-789, 807.
45.	Ittrich H, Peldschus K, Raabe N, et al. Superparamagnetic iron oxide nanoparticles in biomedicine:applications and developments in diagnostics and therapy. Rofo, 2013, 185(12):1149-1166.
46.	涂敏, 朱振舒, 時林森, 等.胃癌轉移淋巴結評估手段的研究現狀及遠景.中華胃腸外科雜志, 2012, 15(2):197-200.
47.	Mortensen MB, Fristrup C, Ainsworth A, et al. Combined pretherapeutic endoscopic and laparoscopic ultrasonography may predict survival of patients with upper gastrointestinal tract cancer. Surg Endosc, 2011, 25(3):804-812.
48.	Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000, 92(3):205-216.
49.	Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma. 2nd English Edition. Gastric Cancer, 1998, 1(1):10-24.
50.	Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer, 2003, 98(7):1521-1530.
51.	Kobayashi M, Yamamoto H, Sugimoto T, et al. Intraoperative local infusion chemotherapy (ILIC) for gastric cancer. Gan To Kagaku Ryoho, 1998, 25(9):1281-1283.
52.	Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol, 1997, 15(1):261-267.
53.	Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phaseⅢtrial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer:A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol, 2000, 18(14):2648-2657.
54.	Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venousinfusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol, 2002, 20(8):1996-2004.
55.	Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006, 355(1):11-20.
56.	Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. PhaseⅢstudy of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group. J Clin Oncol, 2006, 24(31):4991-4997.
57.	依荷芭麗.遲, 任建鴻, 楊林, 等.改良后DCF方案治療進展期胃癌Ⅱ期臨床研究.中國北京.第三屆中國腫瘤內科大會教育集論文集, 2009.
58.	周娜, 應紅艷, 寧曉紅, 等.多西他賽聯合順鉑及氟尿嘧啶(DCF)改良方案治療晚期胃癌療效觀察.基礎醫學與臨床, 2012, 32(12):1456-1460.
59.	Peng Z, Xu S, Li H, et al. Advanced gastric cancer with brain metastasis effectively treated by arterial infusionchemotherapy:A case report. Oncol Lett, 2014, 7(2):449-451.
60.	Kinoshita T, Gotohda N, Kato Y, et al. Laparoscopic proximal gastrectomy with jejunal interposition for gastric cancer in the proximal third of the stomach:a retrospective comparison with open surgery. Surg Endosc, 2013, 27:146-153.
61.	Zhao JG, Qiu F, Xiong JP, et al. A phaseⅡstudy of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer. Anticancer Drugs, 2009, 20(4):281-286.
62.	Park YH, Lee JL, Ryoo BY, et al. Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol, 2008, 61(4):623-629.
63.	Van Ness PH, Peduzzi PN, Quagliarello VJ. Efficacy and effectiveness as aspects of cluster randomized trials with nursing home residents:methodological insights from a pneumonia prevention trial. Contemp Clin Trials, 2012, 33:1124-1131.
64.	Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer:a randomised phaseⅢnoninferiority trial. Ann Oncol, 2009, 20(4):666-673.
65.	Dank M, Zaluski J, Barone C, et al. Randomized phase 3 trial of irinotecan (CPT-11) +5FU/folinic acid (FA) vs CDDP+5FU in 1st-line advanced gastric cancer patients. J Clin Oncol (Meeting Abstracts), 2005, 23(16_suppl):4003.
66.	Ajani JA, Rodriquez W, Bodoky G, et al. Multicenter phaseⅢcomparison of cisplatin/S-1(CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS):Secondary and subset analyses. J Clin Oncol, 2009, 27(15_suppl):4511.
67.	Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial:A phaseⅢstudy of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2(HER2)-positive advanced gastric cancer (GC). J Clin Oncol, 2009, 27(15_suppl):4507.
68.	Satoh T, Leon J, Lopez RI, et al. Quality of life results from a phaseⅢtrial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer. 2010 Gastrointestinal Cancers Symposium, 2010:59-66.
69.	Kang Y, Ohtsu A, Van Cutsem E, et al. AVAGAST:A randomized, double-blind, placebo-controlled, phaseⅢstudy of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol, 2010, 28(18_suppl):LBA4007.
70.	葛來增, 吳仕光, 龔立鵬, 等.胃動脈介入化療栓塞聯合根治術治療進展期胃癌.腫瘤防治研究, 2007, 34(4):300-302.
71.	李東, 吳萍山.術前動脈介入化療治療進展期胃癌的病例對照研究.中國癌癥雜志, 2010, 20(4):290-294.
72.	余傳定, 王新保.胃癌新輔助化療研究進展.中國腫瘤, 2004, 13(11):41-44.
73.	沈琳.進展期胃癌新輔助化療研究與實踐.消化腫瘤雜志:電子版, 2009, 1(1):15-17.
74.	Arkenau HT, Saggese M, Lemech C. Advanced gastric cancer:is there enough evidence to call second-line therapy standard? World J Gastroenterol, 2012, 18(44):6376-6378.
75.	Shrikhande SV, Barreto SG, Talole SD, et al. D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy. World J Surg Oncol, 2013, 11:31.

1. ?季加孚.胃腸道腫瘤的新輔助治療.中國實用外科雜志, 2005, 5(25):261-263.
2. 左朝暉, 歐陽永忠, 湯明, 等.胃癌的綜合治療研究的進展.中華普外科手術學雜志:電子版, 2012, 6(3):319-324.
3. Kong SH, Yang HK. Surgical treatment of gastric gastrointestinal stromal tumor. J Gastric Cancer, 2013, 13(1):3-18.
4. Kosaka T, Ueshige N, Sugaya J, et al. Evaluation of intra-arterial infusion chemotherapy for advanced gastric cancer. Gan To Kagaku Ryoho, 1998, 25(9):1288-1291.
5. Sugarbaker PH. Adjuvant intraperitoneal chemotherapy for advanced primary gastric cancer. Scand J Surg, 2006, 95(4):270-273.
6. 王義平, 王金林, 何世保, 等.介入動脈灌注化療在晚期胃癌中的療效觀察.中外醫療, 2013, 33(33):22-23.
7. 李東, 吳萍山.術前動脈介入化療治療進展期胃癌的病例對照研究.中國癌癥雜志, 2010, 20(4):290-294.
8. Ensminger WD. Intrahepatic arterial infusion of chemotherapy:pharmacologic principles. Semin Oncol, 2002, 29(2):119-125.
9. Pohlen U, Rieger H, Kunick-Pohlen S, et al. PhaseⅡstudy of regional chemotherapy using the hypoxic abdominal perfusion technique in advanced abdominal carcinoma. 5-FU pharmacokinetics, complications and outcome. Anticancer Res, 2007, 27(1B):667-674.
10. 詹曉星, 顏小瓊.介入放射學中的藥代動力學研究.國外醫學:臨床放射學分冊, 1989, 126(6):327-329.
11. 鄒壽椿, 裘華森, 陳方宏, 等.胃癌血供與供血動脈插管化療的臨床觀察.中國實用外科雜志, 1996, 16(11):20-21.
12. Link H, Aigner KR, Kuehn W, et al. Prospective correlative chemosensitivity testing in high-dose intraarterial chemotherapy for liver metastases. Cancer Res, 1986, 46(9):4837-4840.
13. Araki K, Yamamoto H, Kobayashi M, et al. Experimental and clinical study on intraoperative local infusion chemotherapy (ILIC) for advanced gastric carcinoma. Gan To Kagaku Ryoho, 1995, 22(11):1531-1534.
14. Maurer CA, Borner M, Buchler MW, et al. Regional chemotherapy of gastrointestinal cancer. Dig Surg, 1997, 14(1):9-22.
15. 李澍.進展期胃癌術中實施區域性緩釋化療安全性和遠期療效觀察.臨床和實驗醫學雜志, 2014, 13(22):1863-1865.
16. Shchepotin IB, Chorny V, Hanfelt J, et al. Palliative superselective intra-arterial chemotherapy for advanced nonresectable gastric cancer. J Gastrointest Surg, 2000, 3(4):426-431.
17. 朱志東, 蒲永東.氟尿嘧啶經胃左動脈和外周靜脈化療的藥代動力學比較.中國胃腸外科雜志, 2000, 3(1):28-30.
18. 吳鵬, 朱正綱, 葉正寶, 等. 5-氟尿嘧啶-2'-脫氧核苷經胃左動脈介入灌注后的藥代動力學實驗研究.外科理論與實踐, 2004, 9(2):135-139.
19. 徐光煒.胃癌手術輔助化學療法.北京:人民衛生出版社, 1987:251-259.
20. 劉福坤, 陳忠豪, 李國立, 等.胃癌術前介入治療后血管變化與癌組織壞死的關系.世界華人消化雜志, 1998, 6(8):686-688.
21. 孫碎康, 蒲青凡, 嚴律南, 等.胃癌病人術前選擇性動脈栓塞化療對腫瘤血管的影響.中國普通外科雜志, 2002, 11(4):202-204.
22. 楊秀超, 崔振玉, 李正華.經動脈插管灌注抗癌藥提高胃癌手術療效.中華外科雜志, 1994, 32(7):403-404.
23. 徐工學, 李志霞, 陳佛來, 等.術前區域性動脈灌注化療對大腸癌細胞凋亡相關基因的影響.中華外科雜志, 2001, 39(6):436-439.
24. 蒲青凡, 孫碎康, 劉占培, 等.術前胃動脈化療栓塞對胃癌淋巴結轉移灶癌細胞凋亡的影響.中國普外基礎與臨床雜志, 2006, 13(4):427-430.
25. 徐圣德, 高斌, 文剛, 等.術前動脈化療對進展期胃癌細胞凋亡和增殖的影響.介入放射學雜志, 2007, 16(5):353-356.
26. 彭飛, 陳冬峨, 陳華.胃癌p53癌基因表達的Meta分析.數理醫藥學雜志, 2004, 17(6):540-542.
27. Fujimoto S, Watanabe Y, Enomoto K, et al. Studies on preoperative cancer chemotherapy. Methods of preoperative intra-arterial infusion by the use of methotrexate or vinblastine. Cancer, 1969, 24(3):433-441.
28. Peng Z, Xu S, Li H, et al. Advanced gastric cancer with brain metastasis effectively treated by arterial infusionchemotherapy:A case report. Oncol Lett, 2014, 7(2):449-451.
29. 劉銳鋒, 王小琦, 王小虎, 等.術前動脈灌注化療治療局部晚期胃癌的系統評價.腫瘤防治研究, 2012, 39(9):1098-1106.
30. 吳震峰, 朱文強, 曹勤洪, 等.區域動脈灌注化療在進展期胃癌短程新輔助化療中的應用.中華胃腸外科雜志, 2014, 17(11):1092-1095.
31. Zhang CW, Zou SC, Shi D, et al. Clinical significance of preoperative regional intra-arterial infusion chemotherapy for advanced gastric cancer. World J Gastroenterol, 2004, 10(20):3070-3072.
32. Fl?rcken A, Schaefer C, Bichev D, et al. Hepatic arterial infusion chemotherapy for liver metastases from gastric cancer:an analysis in Western patients. Tumori, 2011, 97(1):19-24.
33. Wang YY, Zhang W, Qian S, et al. The effect of locoregional transarterial infusion chemotherapy on liver metastasis after gastric cancer resection. J Int Med Res, 2012, 40(3):1141-1148.
34. 高登鵬, 張霄成, 石秀玲, 等.胃癌術中術后局部化療對癌細胞及患者預后的影響.現代中西醫結合雜志, 2005, 14(19):2535-2537.
35. 李東, 吳萍山, 趙宏.進展期胃癌術前介入化療的療效觀察.腫瘤學雜志, 2003, 9(4):201-203.
36. 李國立, 劉福坤, 陳忠豪, 等.胃癌術前選擇性動脈化療對組織和細胞結構的影響.中華外科雜志, 1997, 35(5):4-6, 66.
37. 肖乾虎, 程中, 盧武勝, 等.胃癌術前行選擇性動脈插管灌注抗癌藥物治療與一般化療的療效比較.臨床外科雜志, 1996, 4(4):190-192.
38. 金雪熙, 楊大明, 徐幼龍, 等.胃癌術前選擇性動脈灌注化療.介入放射學雜志, 2001, 10(6):344-345.
39. 卞育海, 陳治平, 莊捷, 等.術前經動脈化療在胃癌綜合治療中的應用.消化外科, 2002, 1(5):337-339.
40. Kennedy BJ. The unified international gastric cancer staging classification system. Scand J Gastroenterol, 1987, 22(Suppl 133):11.
41. Hwang SW, Lee DH, Lee SH, et al. Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography. J Gastroenterol Hepatol, 2010, 25(3):512-518.
42. Kim EY, Lee WJ, Choi D, et al. The value of PET/CT for preoperative staging of advanced gastric cancer:comparison with contrastenhanced CT. Eur J Radiol, 2011, 79(2):183-188.
43. Kwee RM, Kwee TC. Role of imaging in predicting response to neoadjuvant chemotherapy in gastric cancer. World J Gastroenterol, 2014, 20(7):1650-1656.
44. 葛梅英, 尹化斌, 葛菁芳, 等.小網膜受胃癌侵犯的CT表現及其對病變擴散蔓延的影響研究.實用放射學雜志, 2014(5):786-789, 807.
45. Ittrich H, Peldschus K, Raabe N, et al. Superparamagnetic iron oxide nanoparticles in biomedicine:applications and developments in diagnostics and therapy. Rofo, 2013, 185(12):1149-1166.
46. 涂敏, 朱振舒, 時林森, 等.胃癌轉移淋巴結評估手段的研究現狀及遠景.中華胃腸外科雜志, 2012, 15(2):197-200.
47. Mortensen MB, Fristrup C, Ainsworth A, et al. Combined pretherapeutic endoscopic and laparoscopic ultrasonography may predict survival of patients with upper gastrointestinal tract cancer. Surg Endosc, 2011, 25(3):804-812.
48. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000, 92(3):205-216.
49. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma. 2nd English Edition. Gastric Cancer, 1998, 1(1):10-24.
50. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer, 2003, 98(7):1521-1530.
51. Kobayashi M, Yamamoto H, Sugimoto T, et al. Intraoperative local infusion chemotherapy (ILIC) for gastric cancer. Gan To Kagaku Ryoho, 1998, 25(9):1281-1283.
52. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol, 1997, 15(1):261-267.
53. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phaseⅢtrial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer:A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol, 2000, 18(14):2648-2657.
54. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venousinfusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol, 2002, 20(8):1996-2004.
55. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006, 355(1):11-20.
56. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. PhaseⅢstudy of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group. J Clin Oncol, 2006, 24(31):4991-4997.
57. 依荷芭麗.遲, 任建鴻, 楊林, 等.改良后DCF方案治療進展期胃癌Ⅱ期臨床研究.中國北京.第三屆中國腫瘤內科大會教育集論文集, 2009.
58. 周娜, 應紅艷, 寧曉紅, 等.多西他賽聯合順鉑及氟尿嘧啶(DCF)改良方案治療晚期胃癌療效觀察.基礎醫學與臨床, 2012, 32(12):1456-1460.
59. Peng Z, Xu S, Li H, et al. Advanced gastric cancer with brain metastasis effectively treated by arterial infusionchemotherapy:A case report. Oncol Lett, 2014, 7(2):449-451.
60. Kinoshita T, Gotohda N, Kato Y, et al. Laparoscopic proximal gastrectomy with jejunal interposition for gastric cancer in the proximal third of the stomach:a retrospective comparison with open surgery. Surg Endosc, 2013, 27:146-153.
61. Zhao JG, Qiu F, Xiong JP, et al. A phaseⅡstudy of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer. Anticancer Drugs, 2009, 20(4):281-286.
62. Park YH, Lee JL, Ryoo BY, et al. Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol, 2008, 61(4):623-629.
63. Van Ness PH, Peduzzi PN, Quagliarello VJ. Efficacy and effectiveness as aspects of cluster randomized trials with nursing home residents:methodological insights from a pneumonia prevention trial. Contemp Clin Trials, 2012, 33:1124-1131.
64. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer:a randomised phaseⅢnoninferiority trial. Ann Oncol, 2009, 20(4):666-673.
65. Dank M, Zaluski J, Barone C, et al. Randomized phase 3 trial of irinotecan (CPT-11) +5FU/folinic acid (FA) vs CDDP+5FU in 1st-line advanced gastric cancer patients. J Clin Oncol (Meeting Abstracts), 2005, 23(16_suppl):4003.
66. Ajani JA, Rodriquez W, Bodoky G, et al. Multicenter phaseⅢcomparison of cisplatin/S-1(CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS):Secondary and subset analyses. J Clin Oncol, 2009, 27(15_suppl):4511.
67. Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial:A phaseⅢstudy of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2(HER2)-positive advanced gastric cancer (GC). J Clin Oncol, 2009, 27(15_suppl):4507.
68. Satoh T, Leon J, Lopez RI, et al. Quality of life results from a phaseⅢtrial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer. 2010 Gastrointestinal Cancers Symposium, 2010:59-66.
69. Kang Y, Ohtsu A, Van Cutsem E, et al. AVAGAST:A randomized, double-blind, placebo-controlled, phaseⅢstudy of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol, 2010, 28(18_suppl):LBA4007.
70. 葛來增, 吳仕光, 龔立鵬, 等.胃動脈介入化療栓塞聯合根治術治療進展期胃癌.腫瘤防治研究, 2007, 34(4):300-302.
71. 李東, 吳萍山.術前動脈介入化療治療進展期胃癌的病例對照研究.中國癌癥雜志, 2010, 20(4):290-294.
72. 余傳定, 王新保.胃癌新輔助化療研究進展.中國腫瘤, 2004, 13(11):41-44.
73. 沈琳.進展期胃癌新輔助化療研究與實踐.消化腫瘤雜志:電子版, 2009, 1(1):15-17.
74. Arkenau HT, Saggese M, Lemech C. Advanced gastric cancer:is there enough evidence to call second-line therapy standard? World J Gastroenterol, 2012, 18(44):6376-6378.
75. Shrikhande SV, Barreto SG, Talole SD, et al. D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy. World J Surg Oncol, 2013, 11:31.

Previous Article
Research Progress of Lymph Node Dissection in Treatment of cN0 Papillary Thyroid Microcarcinoma
Next Article
高分辨肛管直腸測壓對肛管括約肌功能障礙的診斷(1例報道)

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research Progress of Preoperative Regional-arterial Chemotherapy in Advanced Gastric Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content